Wednesday, July 8, 2026

Patent intelligence · US

US 11781156

Plakophillin-2 gene therapy methods and compositions

granted A61KA61K48/005A61K48/0058A61K48/0075
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 13
Patent details — US 11781156
Jurisdiction
US
Status
granted
Grant date
Oct 10, 2023
Expiration
Oct 5, 2043
Claims
17
CPC classes
A61K, A61K48/005, A61K48/0058, A61K48/0075
View on Google Patents ↗

Quick answer

US 11781156 (Plakophillin-2 gene therapy methods and compositions) is held by Tenaya Therapeutics, Inc.. Status: granted. Granted Oct 10, 2023. Expires Oct 5, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
17
CPC classes
A61K, A61K48/005, A61K48/0058, A61K48/0075, A61P, A61P9/00

More from Tenaya Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12312345

    Fluoroalkyl-oxadiazoles and uses thereof

    Tenaya Therapeutics, Inc. · Expires May 22, 2045

    granted
  2. US 12201617

    HDAC6 inhibitors for treatment of metabolic disease and HFpEF

    Tenaya Therapeutics, Inc. · Expires Jan 16, 2045

    granted
  3. US 12168778

    Cardiac cell reprogramming with myocardin and ASCL1

    Tenaya Therapeutics, Inc. · Expires Dec 12, 2044

    granted
  4. US 12151001

    Optimized expression cassettes for gene therapy

    Tenaya Therapeutics, Inc. · Expires Nov 21, 2044

    granted
  5. US 12104165

    Adeno-associated virus with engineered capsid

    Tenaya Therapeutics, Inc. · Expires Sep 26, 2044

    granted
  6. US 11926622

    Fluoroalkyl-oxadiazoles and uses thereof

    Tenaya Therapeutics, Inc. · Expires Mar 7, 2044

    granted
  7. US 11913012

    Cardiac cell reprogramming with myocardin and ASCL1

    Tenaya Therapeutics, Inc. · Expires Feb 22, 2044

    granted

Frequently asked questions

What is US patent 11781156?

US 11781156 (Plakophillin-2 gene therapy methods and compositions) is held by Tenaya Therapeutics, Inc.. Status: granted. Granted Oct 10, 2023. Expires Oct 5, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11781156?

Tenaya Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.

When does US 11781156 expire?

Our index shows an expiration date of Oct 5, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.